$25,250.44 speaking Payment -- Takeda Pharmaceuticals to Dr. Amy Phillips
Neurologist Amy Phillips Earns Over $25K for Takeda Pharmaceuticals Speaking Engagement
This page provides a detailed analysis of a $25,250.44 speaking payment from Takeda Pharmaceuticals to Dr. Amy Phillips. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $25,250.44 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Takeda Pharmaceuticals |
| Physician | Dr. Amy Phillips |
| NPI Number | 1240822990 |
| Physician Specialty | Neurology |
| Location | City, MD |
| Date of Payment | 2025-10-10 |
| Related Drug/Device | Ibrance |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Takeda Pharmaceuticals made a $25.3K speaking payment to Amy Phillips, a Neurology specialist in City, MD. The payment was associated with Ibrance. Dr. Amy Phillips received $25,250.44 from Takeda Pharmaceuticals for speaking engagements related to Ibrance. The payment was for serving as faculty or a speaker, indicating an educational or promotional role. This payment occurred on October 10, 2025, and is publicly available through the CMS Open Payments program.
Patient Guidance: What This Payment Means for You
This information details payments made to healthcare providers for educational activities. It is important to understand how these relationships may influence medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements can vary widely depending on the topic, speaker's expertise, and the drug or device being discussed. This amount may be within the typical range for a neurologist presenting on a specialized oncology drug.
Regulatory Context: Sunshine Act Requirements
Payments to physicians from pharmaceutical companies are subject to disclosure under the Sunshine Act (part of the Affordable Care Act) to promote transparency in the healthcare industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-engagement
- pharmaceutical-payments
- neurology
- ibrance
- takeda-pharmaceuticals
- physician-compensation
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $25.3K payment for?
This was a speaking payment of $25.3K from Takeda Pharmaceuticals to Amy Phillips, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Amy Phillips accept pharmaceutical money?
Yes, Amy Phillips received this $25.3K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amy Phillips's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $25.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Neurology?
To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Amy Phillips's relationship with Takeda Pharmaceuticals?
The payment amount is substantial, suggesting significant engagement or a high-value educational program. This $25.3K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Neurology?
The specific drug mentioned, Ibrance, is a cancer treatment, implying the speaking engagement was focused on oncology.
What should patients do after learning about this payment?
This information details payments made to healthcare providers for educational activities. It is important to understand how these relationships may influence medical advice.
What else should I know about this speaking payment?
The payment type is 'speaking', which is a common form of engagement between pharma and healthcare professionals.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.